SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
SciSparc (Nasdaq: SPRC) said on November 20, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds approximately 75% controlling interest, filed an Israeli patent application for a combination therapy of MEAI (5-methoxy-2-aminoindane) and N-acylethanolamines such as PEA targeting depression.
The filing expands a joint IP portfolio with Clearmind Medicine (Nasdaq: CMND); the collaboration has produced 13 patents filed to date covering MEAI and N-acylethanolamine combinations for disorders including alcohol use disorder, cocaine addiction, obesity and depression. The release cites preclinical data supporting MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.
The announcement references World Health Organization data (August 2025) noting ~332 million people living with depression worldwide (≈5.7% of adults).
SciSparc (Nasdaq: SPRC) ha dichiarato il 20 novembre 2025 che NeuroThera Labs (TSXV: NTLX), in cui SciSparc detiene circa il 75% di partecipazione di controllo, ha presentato una richiesta di brevetto israeliana per una terapia di combinazione di MEAI (5-metossio-2-aminoindano) e N-acilethanolamine come PEA mirata alla depressione.
La richiesta amplia una portafoglio IP con Clearmind Medicine (Nasdaq: CMND); la collaborazione ha prodotto 13 brevetti presentati ad oggi che coprono combinazioni di MEAI e N-acilethanolamina per disturbi tra cui disturbo da uso di alcol, uso di cocaina, obesità e depressione. Il comunicato cita dati preclinici a supporto dell'efficacia di MEAI nel ridurre comportamenti dipendenti preservando i normali percorsi di ricompensa.
Il comunicato fa riferimento ai dati dell'Organizzazione Mondiale della Sanità (agosto 2025) che indicano circa 332 milioni di persone nel mondo affette da depressione (≈5,7% degli adulti).
SciSparc (Nasdaq: SPRC) dijo el 20 de noviembre de 2025 que NeuroThera Labs (TSXV: NTLX), en la cual SciSparc posee aproximadamente un participación mayoritaria del 75%, presentó una solicitud de patente en Israel para una terapia de combinación de MEAI (5-metoxi-2-aminoindano) y N-aciletanolaminas como PEA dirigida a la depresión.
La solicitud amplía una cartera conjunta de PI con Clearmind Medicine (Nasdaq: CMND); la colaboración ha producido 13 patentes presentadas hasta la fecha que cubren combinaciones MEAI y N-aciletanolaminas para trastornos como el trastorno por uso de alcohol, la adicción a la cocaína, la obesidad y la depresión. El comunicado cita datos preclínicos que respaldan la eficacia de MEAI para reducir comportamientos adictivos mientras se preservan las rutas normales de recompensa.
El anuncio hace referencia a datos de la Organización Mundial de la Salud (agosto 2025) señalando que ~332 millones de personas padecen depresión en todo el mundo (≈5,7% de los adultos).
SciSparc (나스닥: SPRC)는 2025년 11월 20일에 SciSparc가 약 75% 지배지분을 보유한 NeuroThera Labs (TSXV: NTLX)가 이스라엘 특허 출원을 통해 MEAI(5-methoxy-2-aminoindane)와 N-아실에탄올아민들로 구성된 조합 치료를 Depression을 표적으로 한다고 발표했다고 밝혔다.
출원은 Clearmind Medicine(Nasdaq: CMND)와의 공동 IP 포트폴리오를 확장한다; 이 협력은 지금까지 MEAI와 N-아실에탄올아민 조합을 뇌질환 포함하여 알코올 사용 장애, 코카인 중독, 비만 및 우울증에 대해 지금까지 제기된 특허 13건을 보유하고 있다. 발표에는 MEAI의 중독 행동 감소를 뒷받침하는 전임상 데이터가 인용되어 정상적인 보상 경로를 보존한다는 내용이 있다.
이 발표는 세계보건기구의 데이터(2025년 8월)를 인용하며 전 세계적으로 우울증에 걸린 사람은 약 3억 3200만 명이고 성인 인구의 약 5.7%에 해당한다고 한다.
SciSparc (Nasdaq: SPRC) a déclaré le 20 novembre 2025 que NeuroThera Labs (TSXV: NTLX), dans lequel SciSparc détient environ 75% des droits de contrôle, a déposé une demande de brevet israélienne pour une thérapie de combinaison de MEAI (5-méthoxy-2-aminoindane) et de N-acétylethanolamines telles que PEA visant la dépression.
Le dépôt étend un portefeuille IP conjoint avec Clearmind Medicine (Nasdaq: CMND); la collaboration a produit 13 brevets déposés à ce jour couvrant les combinaisons MEAI et N-acétylethanolamine pour des troubles incluant les troubles liés à l'usage d'alcool, la cocaïne, l'obésité et la dépression. Le communiqué cite données précliniques soutenant l'efficacité du MEAI à réduire les comportements addictifs tout en préservant les voies de récompense normales.
L'annonce fait référence à des données de l'Organisation mondiale de la Santé (août 2025) indiquant environ 332 millions de personnes souffrant de dépression dans le monde (≈5,7% des adultes).
SciSparc (Nasdaq: SPRC) sagte am 20. November 2025, dass NeuroThera Labs (TSXV: NTLX), an dem SciSparc etwa 75% Mehrheitsbeteiligung hält, eine israelische Patentanmeldung für eine Kombinationsbehandlung aus MEAI (5-Methoxy-2-aminoindan) und N-Acyl-Ethanolamin, wie PEA, eingereicht hat, die auf Depression abzielt.
Die Einreichung erweitert ein gemeinsames IP-Portfolio mit Clearmind Medicine (Nasdaq: CMND); die Zusammenarbeit hat bis heute 13 patentierte Anmeldungen hervorgebracht, die MEAI- und N-Acyl-Ethanolamin-Kombinationen für Störungen wie Alkoholgebrauchsstörung, Kokainabhängigkeit, Fettleibigkeit und Depression abdecken. Die Mitteilung zitiert präklinische Daten, die die Wirksamkeit von MEAI bei der Reduzierung süchtig machenden Verhaltens unterstützen, während normale Belohnungswege erhalten bleiben.
Die Ankündigung verweist auf Daten der Weltgesundheitsorganisation (August 2025), wonach weltweit ca. 332 Millionen Menschen unter Depressionen leiden (≈5,7% der Erwachsenen).
SciSparc (بورصة ناسداك: SPRC) قال في 20 نوفمبر 2025 أن NeuroThera Labs (TSXV: NTLX)، التي تمتلك SciSparc فيها نحو 75% مصلحة سيطرة، قد قدمت طلب براءة اختراع إسرائيلية لمجلس علاج مركب من MEAI (5-methoxy-2-aminoindane) و N-الأيليلين-الإيثانول الأميني مثل PEA يستهدف الاكتئاب.
يمدد التقديم محفظة الملكية الفكرية المشتركة مع Clearmind Medicine (Nasdaq: CMND); وقد أنتجت الشراكة 13 براءة اختراع مقدمة حتى الآن تغطي مجموعات MEAI و N-acylethanolamine لاضطرابات بما في ذلك اضطراب استخدام الكحول والإدمان على الكوكايين والسمنة والاكتئاب. وتورد البيان بيانات ما قبل السريرية تدعم فاعلية MEAI في تقليل السلوكيات الإدمانية مع الحفاظ على مسارات المكافأة العادية.
يشير الإعلان إلى بيانات منظمة الصحة العالمية (أغسطس 2025) التي تشير إلى وجود ~332 مليون شخص مصاب بالاكتئاب في جميع أنحاء العالم (≈5.7% من البالغين).
- ~75% controlling interest in NeuroThera held by SciSparc
- Filed an Israeli patent application for MEAI + PEA on Nov 20, 2025
- 13 patents filed so far through the NeuroThera–Clearmind collaboration
- Preclinical data reported supporting MEAI efficacy against addictive behaviors
- Patent status is application; no grant or enforceable IP right yet
- Therapy support limited to preclinical data; no clinical efficacy presented
TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately
The patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine Inc. (Nasdaq: CMND). This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization data from August 2025, major depressive disorder affects, approximately 332 million people worldwide are living with depression. This represents an estimated
This new filing further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed through the collaboration, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary Neurothera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary Neurothera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through Neurothera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About Neurothera Labs Inc.
Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages of the new patent filing, that this therapy has the potential to address depression treatment, and that the patents that have been filed through the collaboration with Clearmind Medicine Inc. have the potential to address alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What did SciSparc (SPRC) announce on November 20, 2025 about NeuroThera?
How much of NeuroThera does SciSparc (SPRC) own?
How many patents have been filed through the NeuroThera–Clearmind collaboration?
Does the SciSparc patent filing mean the MEAI+PEA therapy is clinically proven?
What global depression statistics were cited in the SciSparc announcement?
